Volume | 1,569,975 |
|
|||||
News | - | ||||||
Day High | 0.0135 | Low High |
|||||
Day Low | 0.0111 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Innovation Pharmaceuticals Inc (PK) | IPIX | OTCMarkets | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
0.0135 | 0.0111 | 0.0135 | 0.012 | 0.0135 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
85 | 1,569,975 | $ 0.012205 | $ 19,161 | - | 0.0101 - 0.043 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
15:58:46 | 23,685 | $ 0.012 | USD |
Innovation Pharmaceuticals Inc (PK) Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
5.86M | 514.01M | 342.36M | 18k | -7.04M | -0.01 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Innovation Pharmaceuticals (PK) News
Loading Messages....
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical IPIX Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 0.01615 | 0.018 | 0.0111 | 0.013506 | 308,875 | -0.00415 | -25.7% |
1 Month | 0.01485 | 0.018 | 0.0111 | 0.0152298 | 233,565 | -0.00285 | -19.19% |
3 Months | 0.018 | 0.02 | 0.0101 | 0.0159228 | 276,186 | -0.006 | -33.33% |
6 Months | 0.0225 | 0.023 | 0.0101 | 0.0173514 | 267,401 | -0.0105 | -46.67% |
1 Year | 0.0371 | 0.043 | 0.0101 | 0.0206598 | 463,410 | -0.0251 | -67.65% |
3 Years | 0.2002 | 0.54 | 0.0101 | 0.1620417 | 1,241,763 | -0.1882 | -94.01% |
5 Years | 0.21 | 0.65 | 0.0101 | 0.1802832 | 1,294,892 | -0.198 | -94.29% |
Innovation Pharmaceuticals (PK) Description
An early stage developmental biopharmaceutical company...with six pharmaceutical compound candidates that are designed for treatment of diseases which may be either existing or diseases identified in the future. The Company will initially spend most of its efforts and resources on its anti-cancer compound, Kevetrin, for the treatment of head and neck cancers. |